AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2022
Jan 4, 2022
32883_dirs_2022-01-04_299f8cfc-b7f2-4d2c-ab6f-5fef3e97aa55.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-01-01
Reporting Person: RIOUX PATRICE (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-01 | Stock Options | $3.21 | A | 10000 | Acquired | 2031-12-31 | Common Stock (10000) | Direct |
Footnotes
F1: Stock Options vesting commenced on January 1, 2022 as follows: 833 on January 31, 2022 and each subsequent month-end thereafter.